Discovery, Optimization and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.

To identify novel D3 dopamine receptor (D3R) agonists, we conducted a high-throughput screen using a β-arrestin recruitment assay. Counter-screening of the hit compounds provided an assessment of their selectivity, efficacy, and potency. The most promising scaffold was optimized through medicinal chemistry resulting in enhanced potency and selectivity. The optimized compound, ML417 (20), potently promotes D3R-mediated β-arrestin translocation, G protein activation, and pERK phosphorylation while lacking activity at other dopamine receptors. Screening of ML417 against multiple GPCRs revealed exceptional global selectivity. Molecular modeling suggests that ML417 interacts with the D3R in a unique manner, possibly explaining its remarkable selectivity. ML417 was also found to protect against neurodegeneration of dopaminergic neurons derived from iPSCs. Together with promising pharmacokinetics and toxicology profiles, these results suggest that ML417 is a novel and uniquely selective D3R agonist that may serve as both a research tool and a therapeutic lead for the treatment of neuropsychiatric disorders.

[1]  O. Howes,et al.  Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology , 2020, Neuropharmacology.

[2]  D. Sibley,et al.  A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity , 2020, Science Signaling.

[3]  Z. Xi,et al.  The highly selective dopamine D 3 R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents , 2019, Neuropharmacology.

[4]  Z. Xi,et al.  Newly Developed Dopamine D3 Receptor Antagonists, R-VK4-40 and R-VK4-116, Do Not Potentiate Cardiovascular Effects of Cocaine or Oxycodone in Rats , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[5]  Vsevolod Katritch,et al.  Harnessing Ion-Binding Sites for GPCR Pharmacology , 2019, Pharmacological Reviews.

[6]  Z. Xi,et al.  Investigation of novel primary and secondary pharmacophores, and 3-substitution in the linking chain of a series of highly selective and bitopic dopamine D3 receptor antagonists and partial agonists. , 2019, Journal of medicinal chemistry.

[7]  A. Newman,et al.  2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-protein Coupled Receptors - The Whole is Greater Than the Sum of its Parts. , 2019, Journal of medicinal chemistry.

[8]  A. Newman,et al.  The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists. , 2019, Journal of medicinal chemistry.

[9]  V. Gurevich,et al.  Arrestin-mediated signaling: Is there a controversy? , 2018, World journal of biological chemistry.

[10]  Alan A. Wilson,et al.  Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET study in humans , 2018, Neuropsychopharmacology.

[11]  Z. Xi,et al.  Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects , 2018, Neuropsychopharmacology.

[12]  R. G. Correa,et al.  Dopamine: Functions, Signaling, and Association with Neurological Diseases , 2018, Cellular and Molecular Neurobiology.

[13]  Zhengzhi Wu,et al.  Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists. , 2018, MedChemComm.

[14]  Z. Xi,et al.  The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats , 2017, Neuropharmacology.

[15]  P. Knochel,et al.  Zinc‐Catalyzed Esterification of N‐β‐Hydroxyethylamides: Removal of Directing Groups under Mild Conditions , 2017 .

[16]  Lei Shi,et al.  Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D2 Receptor (D2R) Biased Agonism. , 2017, Journal of medicinal chemistry.

[17]  D. Sibley,et al.  Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R). , 2017, Journal of medicinal chemistry.

[18]  J. Deschamps,et al.  Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor. , 2017, Journal of medicinal chemistry.

[19]  T. Robbins,et al.  Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence , 2017, Neuropsychopharmacology.

[20]  Z. Xi,et al.  Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment. , 2016, Journal of medicinal chemistry.

[21]  D. Sibley,et al.  Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity , 2016, Journal of Medicinal Chemistry.

[22]  S. Ferré,et al.  Evidence for Noncanonical Neurotransmitter Activation: Norepinephrine as a Dopamine D2-Like Receptor Agonist , 2016, Molecular Pharmacology.

[23]  A. Bojarski,et al.  Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties. , 2016, European journal of medicinal chemistry.

[24]  D. Grandy,et al.  Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D2 and D3 Receptors , 2015, Neurochemical Research.

[25]  David E Reichert,et al.  Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics. , 2015, Current pharmaceutical design.

[26]  Z. Xi,et al.  High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice , 2015, Journal of medicinal chemistry.

[27]  Tudor I. Oprea,et al.  Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes , 2015, Cell.

[28]  Mayako Michino,et al.  Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors. , 2015, Chemical communications.

[29]  Aloke K. Dutta,et al.  Dopamine D 3 Agonists in the Treatment of Parkinson's Disease , 2015 .

[30]  M. Rao,et al.  Transfection, selection, and colony-picking of human induced pluripotent stem cells TALEN-targeted with a GFP gene into the AAVS1 safe harbor. , 2015, Journal of visualized experiments : JoVE.

[31]  Lei Shi,et al.  What Can Crystal Structures of Aminergic Receptors Tell Us about Designing Subtype-Selective Ligands? , 2015, Pharmacological Reviews.

[32]  J. Beaulieu,et al.  Dopamine receptors – IUPHAR Review 13 , 2015, British journal of pharmacology.

[33]  Lei Shi,et al.  Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design. , 2014, Advances in pharmacology.

[34]  Shaomeng Wang,et al.  Pramipexole Derivatives as Potent and Selective Dopamine D3 Receptor Agonists with Improved Human Microsomal Stability , 2014, ChemMedChem.

[35]  J. Snyder,et al.  Approaches to design non-covalent inhibitors for human granzyme B (hGrB). , 2014, Organic & biomolecular chemistry.

[36]  Jens Meiler,et al.  Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders , 2014, Nature Reviews Drug Discovery.

[37]  K. Kuder,et al.  Discovery of novel lead in the group of N-substituted piperazine ether derivatives with potential histamine H3 receptor activity. , 2014, Medicinal chemistry (Shariqah (United Arab Emirates)).

[38]  F. Liu,et al.  Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[39]  M. Ferrer,et al.  Discovery and Characterization of a G Protein–Biased Agonist That Inhibits β-Arrestin Recruitment to the D2 Dopamine Receptor , 2014, Molecular Pharmacology.

[40]  Shaomeng Wang,et al.  Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D3 Receptor Antagonists , 2014, Journal of medicinal chemistry.

[41]  Mercedes K. Taylor,et al.  Discovery, Optimization, and Characterization of Novel D2 Dopamine Receptor Selective Antagonists , 2014, Journal of medicinal chemistry.

[42]  A. Newman,et al.  Chiral Resolution and Serendipitous Fluorination Reaction for the Selective Dopamine D3 Receptor Antagonist BAK2-66. , 2014, ACS medicinal chemistry letters.

[43]  G. Stanwood,et al.  Developmental origins of brain disorders: roles for dopamine , 2013, Front. Cell. Neurosci..

[44]  Ruben Abagyan,et al.  Structure-Based Ligand Discovery Targeting Orthosteric and Allosteric Pockets of Dopamine Receptors , 2013, Molecular Pharmacology.

[45]  Lei Shi,et al.  A Single Glycine in Extracellular Loop 1 Is the Critical Determinant for Pharmacological Specificity of Dopamine D2 and D3 Receptors , 2013, Molecular Pharmacology.

[46]  J. Ramos,et al.  New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo. , 2013, Journal of medicinal chemistry.

[47]  Kazushi Watanabe,et al.  Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor. , 2013, Bioorganic & medicinal chemistry.

[48]  Benoît Roux,et al.  AUTOMATED FORCE FIELD PARAMETERIZATION FOR NON-POLARIZABLE AND POLARIZABLE ATOMIC MODELS BASED ON AB INITIO TARGET DATA. , 2013, Journal of chemical theory and computation.

[49]  Jin-Chung Chen,et al.  Intranasal and Subcutaneous Administration of Dopamine D3 Receptor Agonists Functionally Restores Nigrostriatal Dopamine in MPTP-Treated Mice , 2013, Neurotoxicity Research.

[50]  Maria F. Sassano,et al.  Automated design of ligands to polypharmacological profiles , 2012, Nature.

[51]  D. Sibley,et al.  Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. , 2012, Biochemical pharmacology.

[52]  Alexander D. MacKerell,et al.  Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles. , 2012, Journal of chemical theory and computation.

[53]  Shaomeng Wang,et al.  High-affinity and selective dopamine D₃ receptor full agonists. , 2012, Bioorganic & medicinal chemistry letters.

[54]  R. Gainetdinov,et al.  BRET biosensors to study GPCR biology, pharmacology, and signal transduction , 2012, Front. Endocrin..

[55]  Lei Shi,et al.  Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. , 2012, Journal of medicinal chemistry.

[56]  Mark Johnson,et al.  Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization , 2012, Journal of medicinal chemistry.

[57]  P. Sexton,et al.  The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. , 2012, Annual review of pharmacology and toxicology.

[58]  C. Locht,et al.  The ins and outs of pertussis toxin , 2011, The FEBS journal.

[59]  J. Deschamps,et al.  CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist. , 2011, ACS medicinal chemistry letters.

[60]  Avner Schlessinger,et al.  Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.

[61]  H. Kurose,et al.  Gi/o Protein-Dependent and -Independent Actions of Pertussis Toxin (PTX) , 2011, Toxins.

[62]  Alexander D. MacKerell,et al.  Development of the CHARMM Force Field for Lipids. , 2011, The journal of physical chemistry letters.

[63]  Robert R Luedtke,et al.  N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. , 2011, Journal of medicinal chemistry.

[64]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[65]  Kyeong-Man Kim,et al.  Current perspectives on the selective regulation of dopamine D2 and D3 receptors , 2010, Archives of pharmacal research.

[66]  Aloke K. Dutta,et al.  Novel D3 dopamine receptor‐preferring agonist D‐264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine and lactacystin , 2010, Journal of neuroscience research.

[67]  M. Reith,et al.  Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models. , 2010, Journal of medicinal chemistry.

[68]  M. Rao,et al.  Xeno-Free Defined Conditions for Culture of Human Embryonic Stem Cells, Neural Stem Cells and Dopaminergic Neurons Derived from Them , 2009, PloS one.

[69]  Daniel Weintraub,et al.  Dopamine and impulse control disorders in Parkinson's disease , 2008, Annals of neurology.

[70]  Jennifer A. Prescher,et al.  'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. , 2008, Bioorganic & medicinal chemistry.

[71]  M. Reith,et al.  Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity. , 2008, Journal of medicinal chemistry.

[72]  W. Boos,et al.  Maltose and Maltotriose Derivatives as Potential Inhibitors of the Maltose-Binding Protein , 2008 .

[73]  D. Decamp,et al.  Use of a cAMP BRET Sensor to Characterize a Novel Regulation of cAMP by the Sphingosine 1-Phosphate/G13 Pathway* , 2007, Journal of Biological Chemistry.

[74]  A. Antonini,et al.  Valvular heart disease and the use of dopamine agonists for Parkinson's disease. , 2007, The New England journal of medicine.

[75]  B. Roth.  Drugs and valvular heart disease. , 2007, The New England journal of medicine.

[76]  A. Schapira,et al.  Pramipexole protects against MPTP toxicity in non‐human primates , 2006, Journal of neurochemistry.

[77]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[78]  Erin E. Carlson,et al.  Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. , 2005, Journal of medicinal chemistry.

[79]  Sabine Borwege,et al.  Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor , 2004, BMC Biology.

[80]  Mark Slifstein,et al.  In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer (–)‐N‐[11C]propyl‐norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]‐raclopride , 2004, Synapse.

[81]  S. Sakakibara,et al.  Loss of D3 receptors in the zitter mutant rat is not reversed by l-dopa treatment , 2004, Experimental Neurology.

[82]  M. Millan,et al.  Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole , 2003, Experimental Neurology.

[83]  F. Menniti,et al.  Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. , 2003, European journal of pharmacology.

[84]  M. Caron,et al.  Differential Regulation of the Dopamine D2and D3 Receptors by G Protein-coupled Receptor Kinases and β-Arrestins* , 2001, The Journal of Biological Chemistry.

[85]  J. Joyce.  Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. , 2001, Pharmacology & therapeutics.

[86]  N. Meanwell,et al.  Benzoylation of Dianions: Preparation of Monobenzoylated Derivatives of Symmetrical Secondary Diamines , 1999 .

[87]  I. Forbes,et al.  In vitro and in vivo profile of SB 206553, a potent 5‐HT2C/5‐HT2B receptor antagonist with anxiolytic‐like properties , 1996, British journal of pharmacology.

[88]  B. Brooks,et al.  Constant pressure molecular dynamics simulation: The Langevin piston method , 1995 .

[89]  P. Seeman,et al.  Regulation of Anterior Pituitary D2 Dopamine Receptors by Magnesium and Sodium Ions , 1985, Journal of neurochemistry.

[90]  D. Sibley,et al.  Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state. , 1983, Molecular Pharmacology.

[91]  D. Sibley,et al.  Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. , 1982, The Journal of biological chemistry.

[92]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[93]  Amy E. Moritz,et al.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds. , 2018, Cellular signalling.

[94]  D. Saini,et al.  ERK Activation Pathways Downstream of GPCRs. , 2018, International review of cell and molecular biology.

[95]  Arthur Christopoulos,et al.  Bridging the gap: bitopic ligands of G-protein-coupled receptors. , 2013, Trends in pharmacological sciences.

[96]  A. Cavanna,et al.  The Pathophysiology of Impulse control Disorders in Parkinson Disease , 2013, Behavioural neurology.

[97]  G. McCandless,et al.  ORGANIC LETTERS XXXX Vol . XX , No . XX 000 – 000 Chlorination of Aliphatic Primary Alcohols via Triphosgene Triethylamine Activation , 2012 .

[98]  Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. , 2009, Archives of neurology.

[99]  S. Ma,et al.  Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine , 2000, Journal of Neural Transmission.

[100]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[101]  D. Sibley,et al.  Molecular biology of dopamine receptors. , 1992, Trends in pharmacological sciences.